Members of the Cancer Cell Biology (CB) Program study the cell cycle, signal transduction, apoptosis, cell development, cell differentiation, stem cell biology, immune and inflammatory responses and metastasis. They are engaged in determining the drivers of these processes in cancer and translating this knowledge into potential biomarkers and therapeutic approaches and targets for cancer patients. Novel technologies and approaches to address these areas developed by the program include facile animal models to study cancer stem cells, signaling and apoptosis, mass spectrometric analysis of unique tumor epigenetic modifications, functional genomic drug screens and cancer vaccine development. CB has four interconnected focus groups: 1) Signal Transduction and Apoptosis;2) Cell Cycle Regulation and Proliferation;3) Development, Stem Cells and Cancer;4) Inflammation, Immunity and Metastasis. In the prior funding period, CB made major contributions to the field, including: 1) Identified a novel oncogene using a frog model system (Repo-Man);2) Determined the mechanism of action of Silibinin (IP6) a chemopreventive compound;3) Developed novel therapeutics from knowledge of signal transduction, apoptosis and cell cycle pathways (e.g. Mer TK and p27 targets);4) Investigated IL-lb-mediated inflammation's role in melanoma metastasis;5) Discovered novel epigenetic markers (histone H3 K56);6) demonstrated the p53 gain of function mutations confer a worse prognosis than p53 deletion;and, 7) Tested the cancer stem cell hypothesis using novel animal models (BCR and MYC in skin). CB has 66 full members in 20 Departments and 6 schools on the University of Colorado Denver, University of Colorado Boulder, National Jewish Health, and the Colorado State University campuses holding $2.7 million direct costs in NCI grants and $23.7 million direct costs in other cancer-relevant support in the last budget year. Between 2005 and 2010, per capita cancer research funding increased by 40% from $286K to over $400K. CB produced 869 cancer-related publications from 2005 through 2010. Of these, 230 (26.5%) were inter-programmatic publications;66 (7.6%) were intra-programmatic publications;and 36 (4%) were both inter- and intra-programmatic. Thus, 332 (38%) of the total cancer-related publications by memtjers of this program were collaborative. Importantly, more than 2/3 of CB members published collaborative peer reviewed papers in the last funding period with other UCCC members.

Public Health Relevance

The Cancer Cell Biology Program organizes UCCC researchers who study how cellular processes function in the development and progression of cancer. Understanding how cancer changes the way cells function can help biomedical researchers discover new ways to prevent and treat it.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Fitzpatrick, Rikki L; Quimby, Jessica M; Benson, Kellyi K et al. (2018) In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. J Vet Intern Med 32:1951-1957
Lee, Kyubum; Kim, Byounggun; Choi, Yonghwa et al. (2018) Deep learning of mutation-gene-drug relations from the literature. BMC Bioinformatics 19:21
Roof, Allyson K; Jirawatnotai, Siwanon; Trudeau, Tammy et al. (2018) The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. Endocrinology 159:2421-2434
McCubbrey, Alexandra L; Barthel, Lea; Mohning, Michael P et al. (2018) Deletion of c-FLIP from CD11bhi Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis. Am J Respir Cell Mol Biol 58:66-78
Parrish, Janet K; McCann, Tyler S; Sechler, Marybeth et al. (2018) The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. Oncotarget 9:33110-33123
Herbst, Roy S; Redman, Mary W; Kim, Edward S et al. (2018) Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol 19:101-114
Johnson, Monica; Alsaleh, Nasser; Mendoza, Ryan P et al. (2018) Genomic and transcriptomic comparison of allergen and silver nanoparticle-induced mast cell degranulation reveals novel non-immunoglobulin E mediated mechanisms. PLoS One 13:e0193499
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Shearn, Colin T; Pulliam, Casey F; Pedersen, Kim et al. (2018) Knockout of the Gsta4 Gene in Male Mice Leads to an Altered Pattern of Hepatic Protein Carbonylation and Enhanced Inflammation Following Chronic Consumption of an Ethanol Diet. Alcohol Clin Exp Res 42:1192-1205
Giles, Erin D; Jindal, Sonali; Wellberg, Elizabeth A et al. (2018) Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res 20:50

Showing the most recent 10 out of 1634 publications